NCT01712321

Study of Vilazodone to Treat Social Anxiety Disorder

Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: The Medical Research Network · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Vilazodone is effective in the treatment of symptoms of Social Anxiety Disorder among adults.

Detailed description

The proposed study is a 12 week double-blind, placebo-controlled trial in which daily doses of vilazodone 20 to 40 mg/day or matching placebo will be administered on a 1:1 ratio. The study will include 30 outpatients age 18-75 with SAD, generalized subtype who return for at least one post randomization visit where efficacy evaluations are conducted.

Conditions

• Social Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Vilazodone	Vilazodone 20mg or 40mg taken once daily by mouth
DRUG	Placebo	Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth

Timeline

• Start date: 2012-10-01
• Primary completion: 2014-03-01
• Completion: 2014-04-01
• First posted: 2012-10-23
• Last updated: 2014-01-20

Locations

1 site across 1 country: United States